Monoclonal antibodies against endotrophin and the use thereof

US12331110B2 · kind B2 · utility

Assignee

• The Board of Regents of the University of Texas System · US

Inventors

• Ningyan Zhang · Pearland, US
• Dawei BU · Dallas, US
• Zhiqiang An · Houston, US
• Hui DENG · Leiden, NL
• Philipp E. Scherer · Southlake, US

Key dates

• Filing date: Sep 5, 2019
• Grant date: Jun 17, 2025
• Expiry date: Sep 5, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alphas chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.